window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 24, 2026

  • News
  • About Us
Contact Us

neuroscience

  • Neurosciences,Rare Diseases,Research & Development

    Successful treatment for ALS could deliver billions in global value

    New research commissioned by Challenge Works and conducted by the [...]

    November 13, 2025
  • Cell & Gene Therapy,Genomics and sequencing,Neurosciences,Research & Development,Technology and platforms

    Atomic ‘Hook’ in motor protein unlocks neuron cargo delivery secrets

    A team from the University of Tokyo and Juntendo University [...]

    November 6, 2025
  • Cell & Gene Therapy,Central Nervous System,Research & Development

    $2.5M awarded to fuel breakthrough research into tau-driven neurodegenerative diseases

    The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer’s Association, and [...]

    August 15, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Market Access & Commercialization,Oncology,Patient Centricity,Regulatory Affairs,Research & Development

    Neuraxpharm expands global reach with launch of Australian affiliate

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on [...]

    July 22, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development,Rare Diseases

    Game-changing £7.5M prize launches to unlock AI drug targets for ALS

    20 global teams will receive early-stage funding and access to [...]

    June 25, 2025
  • Drug Development,Precision medicine

    Elkedonia raises EUR 11.25 million to develop new treatment for depression and other neuropsychiatric disorders

    New approach targets Elk1 to restore neuroplasticity without sedation or [...]

    June 12, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma randomizes first patient in IMMUNOLIFE Phase 2 NSCLC microbiome study
    Categories: Uncategorised
  • Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions
    Categories: Biologics & Biosimilars, Drug Delivery & Formulation, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
  • NeuroVice seizure oral injury device now available through BlinkRx
    Categories: Central Nervous System, Digital Health, Medical devices, Patient Centricity, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top